Literature DB >> 20070256

The emerging importance of group II PAKs.

Claire M Wells1, Gareth E Jones.   

Abstract

The Rho-family GTPases Rho Rac and Cdc42 regulate many intracellular processes through their interaction with downstream effector proteins. The PAKs (p21-activated kinases) are a family of effector proteins for Rac and Cdc42. PAKs are important regulators of actin cytoskeletal dynamics, neurite outgrowth, cell survival, hormone signalling and gene transcription. There are six mammalian PAKs that can be divided into two groups: group I PAKs (PAK1-3) and group II PAKs (PAK4-6). Although the two PAK groups are architecturally similar, there are differences in their mode of regulation, suggesting that their cellular functions are likely to be different. Whereas much is known about group I PAKs, less is known about the more recently discovered PAK4, PAK5 and PAK6. This review will focus on the latest structural and functional results relating to the group II PAKs and discuss the emerging importance of group II PAKs in disease progression.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20070256     DOI: 10.1042/BJ20091173

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  64 in total

1.  PAK6 targets to cell-cell adhesions through its N-terminus in a Cdc42-dependent manner to drive epithelial colony escape.

Authors:  Elizabeth M Morse; Xiaowen Sun; Jordan R Olberding; Byung Hak Ha; Titus J Boggon; David A Calderwood
Journal:  J Cell Sci       Date:  2015-11-23       Impact factor: 5.285

Review 2.  Signaling, Regulation, and Specificity of the Type II p21-activated Kinases.

Authors:  Byung Hak Ha; Elizabeth M Morse; Benjamin E Turk; Titus J Boggon
Journal:  J Biol Chem       Date:  2015-04-08       Impact factor: 5.157

3.  Type II p21-activated kinases (PAKs) are regulated by an autoinhibitory pseudosubstrate.

Authors:  Byung Hak Ha; Matthew J Davis; Catherine Chen; Hua Jane Lou; Jia Gao; Rong Zhang; Michael Krauthammer; Ruth Halaban; Joseph Schlessinger; Benjamin E Turk; Titus J Boggon
Journal:  Proc Natl Acad Sci U S A       Date:  2012-09-17       Impact factor: 11.205

4.  Identification of neuronal substrates implicates Pak5 in synaptic vesicle trafficking.

Authors:  Todd I Strochlic; Susanna Concilio; Julien Viaud; Ryan A Eberwine; Lisa Epstein Wong; Audrey Minden; Benjamin E Turk; Markus Plomann; Jeffrey R Peterson
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-27       Impact factor: 11.205

5.  Maternal pak4 expression is required for primitive myelopoiesis in zebrafish.

Authors:  Sheran H W Law; Thomas D Sargent
Journal:  Mech Dev       Date:  2012-09-29       Impact factor: 1.882

6.  WNK1 protein kinase regulates embryonic cardiovascular development through the OSR1 signaling cascade.

Authors:  Jian Xie; Joonho Yoon; Sung-Sen Yang; Shih-Hua Lin; Chou-Long Huang
Journal:  J Biol Chem       Date:  2013-02-05       Impact factor: 5.157

7.  Do PAKs make good drug targets?

Authors:  Zhuo-Shen Zhao; Ed Manser
Journal:  F1000 Biol Rep       Date:  2010-09-23

Review 8.  Molecular physiology of SPAK and OSR1: two Ste20-related protein kinases regulating ion transport.

Authors:  Kenneth B Gagnon; Eric Delpire
Journal:  Physiol Rev       Date:  2012-10       Impact factor: 37.312

9.  PF-3758309, p21-activated kinase 4 inhibitor, suppresses migration and invasion of A549 human lung cancer cells via regulation of CREB, NF-κB, and β-catenin signalings.

Authors:  Byung Jun Ryu; Hyuk Lee; Seong-Ho Kim; Jung-Nyoung Heo; Sik-Won Choi; Jeong-Tae Yeon; Jeongmin Lee; Jongsung Lee; Jae Youl Cho; Seong Hwan Kim; Sang Yeol Lee
Journal:  Mol Cell Biochem       Date:  2013-12-24       Impact factor: 3.396

10.  The Rac GTPase effector p21-activated kinase is essential for hematopoietic stem/progenitor cell migration and engraftment.

Authors:  Adrienne M Dorrance; Serena De Vita; Maria Radu; Pavankumar N G Reddy; Meaghan K McGuinness; Chad E Harris; Ronald Mathieu; Steven W Lane; Rachelle Kosoff; Michael D Milsom; Jonathan Chernoff; David A Williams
Journal:  Blood       Date:  2013-01-18       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.